登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002728 证券简称：特一药业 公告编号：2025-058 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或者重大 遗漏。 根据中国证券监督管理委员会《上市公司募集资金监管规则》《深圳证券交易所上市公司自律监管指引 第1号——主板上市公司规范运作》以及《深圳证券交易所上市公司自律监管指南第2号——公告格式》 的相关规定，特一药业集团股份有限公司（以下简称"公司"）董事会编制了截至2025年6月30日募集资 金存放、管理与使用情况的专项报告。 一、募集资金基本情况 （一）扣除发行费用后的实际募集资金金额和资金到位时间 1、2017年公开发行可转换公司债券募集资金 经中国证券监督管理委员会证监许可[2017]2004号文《关于核准特一药业集团股份有限公司公开发行可 转换公司债券的批复》核准，本公司向社会公开发行面值总额3.54亿元的可转换公司债券，每张面值 100元，共计354万张，期限6年。公司本次发行可转债募集资金总额为人民币354,000,000.00元，利息为 12,776.67元，扣除承销费用、保荐费人民币 ...

证券代码：002728 证券简称：特一药业 公告编号：2025-056 特一药业集团股份有限公司 关于第六届董事会第三次会议决议的公告 特一药业集团股份有限公司（以下简称"特一药业"或"公司"）第六届董事会第 三次会议于 2025 年 8 月 21 日 10:00 在公司子公司海南海力制药有限公司会议室采用现 场及电子通信方式召开，会议通知于 2025 年 8 月 19 日以电子邮件方式发出，会议应出 席董事 6 名，实际出席 6 名。公司非董事高级管理人员列席了本次会议。会议的召集、 召开符合《公司法》和《公司章程》的相关规定。 二、董事会会议审议情况 会议由董事长许荣煌主持，全体董事经过审议，以现场和电子通信方式进行表决， 通过了如下决议： 公司 2025 年 1-6 月的经营情况及财务状况已经公司相关部门编制完成，具体内容 详见《2025 年半年度报告》，该报告拟于 2025 年 8 月 22 日对外报出。 公司 2025 年半年度财务信息已由公司审计委员会审议并取得了全体委员明确同意 的意见。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、董事 ...

Group 1: Company Performance - In the first half of 2025, the company achieved total revenue of 491 million yuan, representing a year-on-year increase of 56.54% [1] - The net profit attributable to shareholders reached 38.01 million yuan, showing a significant year-on-year growth of 1313.23% [1] - The sales volume of the core product "Te Yi" cough tablets reached 331 million pieces, indicating a steady recovery in sales [1] Group 2: Market Trends - The demand for pharmaceutical products in the domestic market is diversifying due to rising living standards and increasing health awareness among residents [2] - There is a growing demand not only for common disease treatment drugs but also for preventive healthcare, chronic disease management, and innovative drugs [2] - The integration of new technologies such as artificial intelligence and big data with the pharmaceutical industry is expected to drive digital transformation and intelligent upgrades [2] Group 3: Strategic Initiatives - The company is actively engaged in product research and development as well as brand building [3] - The company has invested a total of 172 million yuan in brand development in the first half of the year, which has enhanced the brand's visibility and influence, particularly among younger and online consumer groups [3] - The company's integrated advantage of "raw materials + formulations" is expected to become more prominent against the backdrop of rising raw material prices [3]

Core Insights - The company reported a significant increase in revenue and net profit for the first half of 2025, indicating strong financial performance [2] Financial Performance - The company's operating revenue for the first half of 2025 was approximately 491 million yuan, representing a year-on-year increase of 56.54% [2] - The net profit attributable to shareholders was around 38.01 million yuan, showing a substantial year-on-year increase of 1313.23% [2] - Basic earnings per share reached 0.08 yuan, which is a year-on-year increase of 1500% [2]

每天三分钟公告很轻松 飞鹿股份（300665）：筹划公司控制权变更事项 22日起停牌；中国石化和东贝集团拟回购公司股份； 万泰生物：公司九价HPV疫苗首次获得批签发证明；格林美：公司与蔚蓝锂芯签署战略合作协议；特一 药业和千方科技半年报净利同比增逾10倍…… 今日看点 ▼聚焦一：飞鹿股份：实控人筹划公司控制权变更事项 22日起停牌 公司收到控股股东、实际控制人章卫国通知，章卫国正在筹划公司控制权变更相关事宜，方案涉及股份 协议转让、表决权委托及公司向特定对象发行股份。目前，相关方正在就具体交易方案、协议等相关事 项进行论证和磋商。 经公司向深圳证券交易所申请，公司股票自2025年8月22日（星期五）开市起停牌，预计停牌时间不超 过2个交易日。 ▼聚焦二：中国石化和东贝集团拟回购公司股份 中国石化：公司拟使用不低于5亿元、不超过10亿元的自有资金和回购专项贷款，通过上海证券交易所 系统以集中竞价交易方式回购公司发行的A股股份，回购价格为不超过8.72元/股，本次回购股份的期限 自董事会批准方案之日起不超过3个月，回购的股份将全部注销并减少注册资本。按回购股份价格上限 8.72元/股测算，预计本次回购A股股份数量 ...

Buyback and Shareholder Actions - Sinopec plans to repurchase A-shares with a total fund of no less than RMB 5 billion and no more than RMB 10 billion, potentially reducing its registered capital [1] - Hengbang Mining intends to reduce its stake in the Hong Kong-listed company, WanGuo Gold, by up to 40 million shares, representing approximately 3.69% of WanGuo's total share capital [5] Product Approvals and Market Launches - Wantai Biological's nine-valent HPV vaccine has received the batch release certificate, marking its official market launch and enhancing the company's product lineup [1] - Changchun High-tech's subsidiary has received acceptance for the clinical trial application of GenSci143, a dual-specific antibody drug, which may provide new treatment options for certain tumors [7] Financial Performance - Hongxin Electronics reported a 15.01% increase in revenue to RMB 3.494 billion and a 9.85% rise in net profit to RMB 53.99 million for the first half of 2025 [2] - Sanwei Xinan experienced a net loss of RMB 29.39 million in the first half of 2025, despite a 15.19% increase in revenue to RMB 195 million [3] Corporate Developments - TianTan Bio received a commitment from its controlling shareholder to resolve new competition issues arising from a recent acquisition [4] - Feilu Co. announced a potential change in control, leading to a temporary suspension of its stock trading [8] Investment and Expansion - Jinbei Electric's subsidiary has signed a purchase agreement for a factory in Europe, marking significant progress in establishing its European production base [1] - Shengshi Technology plans to establish a wholly-owned subsidiary to integrate AI and humanoid robot technology with innovative toy products, investing RMB 10 million [6]

北京商报讯（记者 丁宁）8月21日晚间，特一药业（002728）披露2025年半年度报告显示，上半年公司 实现营业收入4.91亿元，同比增长56.54%；归属净利润3800.77万元，同比增长1313.23%。 ...

证券日报网讯 8月21日晚间，特一药业发布2025年半年度报告摘要称，2025年半年度公司实现营业收入 491，142，874.06元，同比增长56.54%；归属于上市公司股东的净利润为38，007，729.88元，同比增 长1313.23%。 （编辑 任世碧） ...

Growth - Teva Pharmaceutical reported a net profit of 38.01 million yuan in the first half of the year, a year-on-year increase of 1313.23% [1] - Qianfang Technology achieved a net profit of 170 million yuan, up 1287.12% year-on-year [1] - Tianyu Digital Science and Technology recorded a net profit of 23.62 million yuan, reflecting a 453.67% increase [1] - Suzhou Gude reported a net profit of 43.70 million yuan, up 310.28% year-on-year [1] - Sainuo Medical achieved a net profit of 13.84 million yuan, an increase of 296.54% [1] - Runfeng Co., Ltd. reported a net profit of 556 million yuan, up 205.62% year-on-year [1] - Guodian Nanzi achieved a net profit of 159 million yuan, reflecting a 197.03% increase [1] - Ruijie Networks reported a net profit of 452 million yuan, up 194% year-on-year [1] - Zhongjing Technology achieved a net profit of 25.74 million yuan, an increase of 144.05% [1] - China National Materials Technology reported a net profit of 999 million yuan, up 114.92% year-on-year [1] - Lante Optics achieved a net profit of 103 million yuan, reflecting a 110.27% increase [1] - Yidao Information reported a net profit of 11.41 million yuan, up 96.02% year-on-year [1] - Qianzhao Optoelectronics achieved a net profit of 69.23 million yuan, an increase of 88.04% [1] - Ruile New Materials reported a net profit of 166 million yuan, up 74.22% year-on-year [1] - Lvtian Machinery achieved a net profit of 140 million yuan, reflecting a 64.36% increase [1] - Mega Chip Color reported a net profit of 110 million yuan, up 48.83% year-on-year [1] - Jiaojian Co., Ltd. achieved a net profit of 113 million yuan, an increase of 48.66% [1] - Huhua Electronics reported a net profit of 1.683 billion yuan, up 47.50% year-on-year [1] - Sany Heavy Industry achieved a net profit of 5.216 billion yuan, reflecting a 46% increase [1] - Goodix Technology reported a net profit of 431 million yuan, up 35.74% year-on-year [1] - Allwinner Technology achieved a net profit of 161 million yuan, an increase of 35.36% [1] - Bichu Electronics reported a net profit of 640 million yuan, up 30.32% year-on-year [1] - Ganneng Co., Ltd. achieved a net profit of 438 million yuan, reflecting a 29.39% increase [1] - Weigao Medical reported a net profit of 492 million yuan, up 28.07% year-on-year [1] - GoerTek achieved a net profit of 1.417 billion yuan, reflecting a 15.65% increase [1] - Huason Pharmaceutical reported a net profit of 53.95 million yuan, up 14.27% year-on-year [1] - Gaoxin Development achieved a net profit of 66.92 million yuan, an increase of 14.06% [1] - Shanghai Jahwa reported a net profit of 266 million yuan, up 11.66% year-on-year [1] Stable Growth - Hangcha Group reported a net profit of 1.121 billion yuan, reflecting an increase of 11.38% year-on-year [2] - Dong'e Ejiao achieved a net profit of 818 million yuan, up 10.74% [2] - Beikong Technology reported a net profit of 54.31 million yuan, an increase of 10.59% [2] - Hongxin Electronics achieved a net profit of 53.99 million yuan, up 9.85% year-on-year [2] - Huace Testing reported a net profit of 467 million yuan, reflecting a 7.03% increase [2] - Samsung Medical achieved a net profit of 1.230 billion yuan, up 6.93% year-on-year [2] - Jiangzhong Pharmaceutical reported a net profit of 522 million yuan, reflecting a 5.80% increase [2] - Hualing Cable achieved a net profit of 63.64 million yuan, up 4.74% year-on-year [2] - Kuaijishan reported a net profit of 93.88 million yuan, reflecting a 3.41% increase [2] - Laishen Tongling achieved a net profit of 60.61 million yuan, turning from loss to profit [2] - Yunnan Geology reported a net profit of 22.15 million yuan, turning from loss to profit [2] - Shandong Steel achieved a net profit of 1.253 million yuan, turning from loss to profit [2] Decline and Loss - Zhongtian Rocket reported a net profit of 394,460 yuan, a year-on-year decrease of 80.74% [2] - Liuhua Co., Ltd. achieved a net profit of 344,280 yuan, down 78.01% year-on-year [2] - Qiaqia Food reported a net profit of 886.42 million yuan, a decrease of 73.68% [2] - Hangjin Technology achieved a net profit of 1.372 million yuan, down 58.38% year-on-year [2] - Taiping Bird reported a net profit of 7.771 million yuan, a decrease of 54.61% [2] - Canadian Solar reported a net profit of 731 million yuan, down 41.01% year-on-year [2] - Sinopec achieved a net profit of 21.483 billion yuan, a decrease of 39.8% [2] - Fulejia reported a net profit of 230 million yuan, down 32.54% year-on-year [2] - Palin Bio reported a net profit of 236 million yuan, down 27.89% [2] - Yiwei Lithium Energy achieved a net profit of 1.605 billion yuan, down 24.9% year-on-year [2] - Jinguang Electric reported a net profit of 42.34 million yuan, down 17.16% [2] - Hexing Co., Ltd. achieved a net profit of 107 million yuan, down 16.98% year-on-year [2] - Electric Investment Production and Financing reported a net profit of 459 million yuan, down 13.41% [2] - Tiantan Biological achieved a net profit of 633 million yuan, down 12.88% year-on-year [2] - Huali Group reported a net profit of 1.671 billion yuan, down 11.06% [2] - Zhongyou Engineering achieved a net profit of 470 million yuan, down 10.87% year-on-year [2] Further Losses - Chongda Technology reported a net profit of 222 million yuan, down 6.19% year-on-year [3] - Xinhua Department Store achieved a net profit of 86.01 million yuan, down 2.52% [3] - Zhuosheng Micro reported a net loss of 147 million yuan, turning from profit to loss [3] - Penghui Energy reported a net loss of 88.23 million yuan, turning from profit to loss [3] - Yipin Hong reported a net loss of 73.54 million yuan, turning from profit to loss [3] - Zhongbing Hongjian reported a net loss of 40.71 million yuan, turning from profit to loss [3] - Sanwei Xinan reported a net loss of 29.39 million yuan, turning from profit to loss [3] - Anyuan Coal reported a net loss of 290 million yuan [3] - Keda Xunfei reported a net loss of 239 million yuan [3] - Jishi Media reported a net loss of 23.2 million yuan [3] - Nanjing Chemical Fiber reported a net loss of 88.93 million yuan [3] - Guangsheng Tang reported a net loss of 66.69 million yuan [3] - Chutian Long reported a net loss of 39.77 million yuan [3]

Group 1: Company Performance - Sinopec reported a revenue of 1.4 trillion yuan and a net profit of 23.75 billion yuan for the first half of 2025, with a cash dividend of 0.088 yuan per share, representing a payout ratio of 49.7% [1] - GoerTek achieved a net profit of 1.42 billion yuan, marking a year-on-year increase of 15.65%, despite a revenue decline of 7.02% to 37.55 billion yuan [2] - Gree Electric announced a cash dividend of 20 yuan per 10 shares, totaling 11.17 billion yuan, based on a share base of 5.585 billion shares [3] - Jishi Media reported a revenue of 999.7 million yuan, with a net loss of 232 million yuan for the first half of 2025 [4] - Changchun High-tech's subsidiary received approval for a clinical trial of a dual-specific antibody drug, GenSci143, targeting B7-H3 and PSMA [5] - Greenme announced a strategic partnership with Weilan Lithium to develop high-energy battery materials and solid-state battery technologies [6] Group 2: Share Buybacks and Reductions - Sinopec plans to repurchase shares worth between 5 billion and 10 billion yuan through the Shanghai Stock Exchange [26] - Jiangxi Copper intends to reduce its stake in Zhongyin Securities by up to 3%, equating to 83.34 million shares [7] - Hengbang Mining plans to reduce its stake in the Hong Kong-listed company, WanGuo Gold, by up to 3.69% of its total share capital [10] Group 3: New Product Developments - Renhe Pharmaceutical's subsidiary is developing a brain-machine interaction smart glasses product, which is currently in the testing phase and has not yet generated sales revenue [11] - TianTan Bio received a commitment from its controlling shareholders to resolve new competition issues arising from a recent acquisition [12] - XianDao Intelligent has successfully developed a mass production solution for solid-state batteries and received repeat orders for related products [13] - Zejing Pharmaceutical received approval for clinical trials of ZG005 and ZGGS18 in combination with a cancer treatment drug [14] - Wantai Bio received a production approval for its nine-valent HPV vaccine, marking a new revenue stream [15]